1[1]Moller DR. Treatment of sarcoidosis --from a basic science point of view. J Intern Med,2003,253:31 ～40
2[2]Anaya JM, Espinoza LR. Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseases. J Rheumatol, 1995,22:595～ 599
3[3]Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor - alpha production by pentoxifylline. Biochem Biophys Res Commun, 1988, 155:1230～ 1236
5[5]Benbernou N, Esnault S, Potron G, et al. Regulatory effects of pentoxifylline on T - helper cell - derived cytokine production in human blood cells. J Cardiovasc Pharmacol, 1995,25 (suppl.2) :S75 ～S79
6[6]Moller DR, Wysocka M, Greenlee BM,et al. Inhibition of human interleukin- 12 production by pentoxifylline. Immunology,1997,91:197 ～203
7[7]Rieckmann P, Weber F, Gunther A, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol, 1996,64:193 ～ 200
8[8]Silva JC,Rocha MF, Lima AA, et al. Effects of pentoxifylline and nabumetone on the scrum levels of IL - 1 beta and TNFalpha in rats with adjuvant arthritis. Inflamm Res,2000,49:14 ～ 19
9[9]Kiely PD, Gillespie KM, Oliveira DB. Oxpentifylline inhibits tumor necrosis factor - alpha mRNA transcription and protects against arthritis in mercuric chloride - treated brown Norway rats. Eur J Immunol, 1995,25:2899 ～ 2906
10[10]Chen YL, Le - Vraux V, Giroud JP, et al. Anti - tumor necrosis factor properties of non - peptide drugs in acute - phase responses. Eur J Pharmacol, 1994,271:319 ～ 327
二级参考文献8
1Huang F, Gu J, Zhao W, et al. One-year open-hbel trial of thalidomide in ankylosing spondylitis. Arthritis Rheum (Arthritis Care Res), 2002,47: 249-254.
2Davis J, Huang F, Maksymowych WP. New therapies for ankylosing spondylitis: etanercept, thalidomide and pamidronate. Rheum Dis Clin North Am, 2003,29 : 501-517.
3Huang F, Wei J, Breban M. Thalidomide in ankylosing spondylitis.Clin Exp Rheumatol, 2002,20: S158-161.
4Huang F, Gu J, Zhao W, et al. Therapeutic effect and molecular targets of thalidomide in refractory ankylosing spondylitis. Arthritis Rheum,2001,44 : S275.
5Gorman J, Sack K, Davis J. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med, 2002,346:1349-1356.
6Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet, 2002,359:1187.
7Antoni C,Bmun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol, 2002,20: S152-157.
2Stuart JM, Cremer MA, Townes AS, et al. Type Ⅱ collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med, 1982, 155: 1-16.
3Angelides NS. Continuous infusion treatment with pentoxifylline in patients with severe peripheral vascular occlusive disease. Angiology, 1986, 37: 555-564.
4Bath PM, Bath-Hextall FJ. Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrane Database Syst Rev, 2004, (3): CD000162.
5Ustunsoy H, Sivrikoz MC, Tarakcioglu M, et al. The effects of pentoxifylline on the myocardial inflammation and ischemia- reperfusion injury during cardiopulmonary bypass. J Card Surg, 2006, 21: 57-61.
6Haque K, Mohan P. Pentoxifylline for neonatal sepsis. Cochrane Database Syst Rev, 2003, (4): CD004205.
7Wanchu A, Bhatnagar A, Bambery P, et al. Prevention of opportunistic infections in HIV infection by pentoxiphylline.Indian J Med Res, 2006, 124: 705-708.
8Clerici M, Piconi S, Balotta C, et al. Pentoxifylline improves cell- mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons. J Infect Dis, 1997, 175: 1210-1215.
9Danielsson A, Karlsson E, Delle U, et al. The biological effect of pentoxifylline on the survival of human head and neck cancer cells treated with continuous low and high dose-rate irradiation. J Cancer Res Clin Oncol, 2005, 131: 459-467.
10Goodfield MJ, Rowell NR. Treatment of peripheral gangrene due to systemic sclerosis with intravenous pentoxifylline. Clin Exp Dermatol, 1989, 14: 161-162.
